EditForce
Latest round
- Series D
Last raised
- May 2023
Total raised
- $39M
Investors
- 14
About EditForce
Based in Japan, EditForce Inc.EditForce Inc. was founded in 2015 in Fukuoka-shi, Japan, focusing on advanced RNA editing technologies.EditForce Inc. specializes in innovative RNA editing technologies, which serve as the foundation for their core offerings in the fields of pharmaceuticals, agriculture, and various industrial applications. The company has developed a unique gene manipulation technique based on the PPR (Pentatricopeptide Repeat) protein discovered in plants, differentiating it from traditional RNA editing methods. Their primary focus is on drug development, where they aim to establish effective treatments for various diseases by leveraging their advanced editing capabilities. These products are targeted at a diverse client base that includes pharmaceutical companies, research institutions, and agricultural firms across global markets, such as North America, Europe, and Asia.EditForce's revenue model is grounded in partnerships and collaborations with pharmaceutical companies and research institutions, which utilize their proprietary RNA editing technologies in drug development and research initiatives. These transactions are structured as B2B agreements, where EditForce provides access to its technology through licensing arrangements or collaborative research contracts. The company focuses on creating value through strategic alliances, promoting long-term relationships that facilitate ongoing development and commercialization of their innovative solutions. Specific pricing plans for individual services or products are determined based on the nature of the collaboration and the scope of the projects, ensuring tailored financial arrangements that align with client objectives.In May 2023, EditForce Inc. The company plans to launch new RNA editing products targeting specific applications in pharmaceuticals and agriculture, with expected releases in the next 12-18 months.
Who invested in EditForce
14 investors across 4 rounds
See all investors in EditForce
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about EditForce
Who invested in EditForce?
EditForce has 14 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EditForce raised?
EditForce has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did EditForce last raise money?
EditForce's most recent round on record is a Series D, in May 2023.
What does EditForce do?
EditForce is a biotechnology company.
Where is EditForce headquartered?
EditForce is headquartered in Fukuoka-shi, Japan.
Which VCs invest in companies like EditForce?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at EditForce's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like EditForce? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.